

Comparable to  
Form PTO-1449

Atty. Docket No.

N-7362 RSM  
Customer No. 23456

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Marnett, et al.

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

1614

[illegible]

RECEIVED  
MAR -4 2002  
TECH CENTER 1600/2900

MISCELLANEOUS DOCUMENTS

Date Considered

11/3/04

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JAN 10 2002  
TECH CENTER 1600/2900  
Page 1 of 3

Comparable to  
Form PTO-1449


U.S. Department of Commerce  
Patent & Trademark Office

Atty. Docket No.

Serial No.

N-7362 RSM  
Customer No. 23456

09/924,082



INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicant

Lawrence J. Marnett, et al.

Filing Date  
August 7, 2001

Group  
1651

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date If Appropriate
Y	AA	3,632,627	January 4, 1972	Gordon, et al.			
	AB	4,675,281	June 23, 1987	Lands, et al			
	AC	5,047,354	September 10, 1991	Foegh, et al.			
	AD	5,162,504	November 10, 1992	Horszewicz			
	AE	5,459,239	October 17, 1995	O'Neill, et al.			
	AF	5,474,903	December 12, 1995	Huland			
	AG	5,475,021	December 12, 1995	Marnett, et al			
	AH	5,543,297	August 6, 1996	Cromlish, et al			
	AI	5,589,575	December 31, 1996	Cohen, et al.			
	AJ	5,700,654	December 23, 1997	Roberts et al			
	AK	5,731,343	March 24, 1998	Feng, et al.			
	AL	5,756,092	May 26, 1998	Michelet, et al.			
	AM	5,837,479	November 17, 1998	Young, et al.			
	AN	5,858,694	January 12, 1999	Piazza, et al.			
	AO	5,858,696	January 12, 1999	Roberts, et al.			
	AP	5,874,235	February 23, 1999	Chan, et al			
	AQ	5,891,622	April 6, 1999	Morrow, et al.			
	AR	5,945,675	August 31, 1999	Malins			
	AS	5,958,978	September 28, 1999	Yamazaki, et al.			
	AT	5,973,191	October 26, 1999	Marnett, et al.			
	AU	5,995,645	November 30, 1999	Soenksen, et al.			
	AV	5,999,843	December 7, 1999	Anbar			
1/4	AW	6,045,773	April 4, 2000	Isakson, et al.			
2/4	AX	6,107,049	August 22, 2000	Allard, et al.			

MISCELLANEOUS DOCUMENTS

Y	AY	KALGUTAR, et al.; Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors; PNAS January 18, 2000; 97(2) 925-930.
Y	AZ	KOZAK, et al.; Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2; The Journal of Biological Chemistry October 27, 2000; 43:33744-33749.
Y	BA	KOZAK, et al.; Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol; JBP Papers in Press June 11, 2001
Y	BB	LANDS, et al.; Phospholipid precursors of prostaglandins; Biochem. Biophys. Acta 1968; 164:426-429. ✓
Y	BC	PRESCOTT; A thematic series on oxidation of lipids as a source of messengers; J.Biol. Chem.; 274:22901. ✓

Examiner:

Date Considered

11/4/04


\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
Page 3 of 3  
JUN 10 2002  
TECH CENTER 1600/2900  
63




TECH CENTER 1600/2900  
JAN 22 2001

RECEIVED

<b>Comparable Form PTO-449</b> <b>U.S. Department of Commerce Patent &amp; Trademark Office</b>		<b>Atty. Docket N .</b> N-7362 RSM Customer No. 23456		<b>Serial No.</b> 09/924,082			
		<b>Applicant</b> Lawrence J. Marnett, et al.					
		<b>Filing Date</b> August 7, 2001		<b>Group</b> 1651			
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
	AA	3,632,627	January 4, 1972	Gordon, et al.			
	AB	4,675,281	June 23, 1987	Lands, et al			
	AC	5,047,354	September 10, 1991	Foegh, et al.			
	AD	5,162,504	November 10, 1992	Horoszewicz			
	AE	5,459,239	October 17, 1995	O'Neill, et al.			
	AF	5,474,903	December 12, 1995	Huland			
	AG	5,475,021	December 12, 1995	Marnett, et al			
	AH	5,543,297	August 6, 1996	Cromlish, et al			
	AI	5,589,575	December 31, 1996	Cohen, et al.			
	AJ	5,700,654	December 23, 1997	Roberts et al			
	AK	5,731,343	March 24, 1998	Feng, et al.			
	AL	5,756,092	May 26, 1998	Michelet, et al.			
	AM	5,837,479	November 17, 1998	Young, et al.			
	AN	5,858,694	January 12, 1999	Piazza, et al.			
	AO	5,858,696	January 12, 1999	Roberts, et al.			
	AP	5,874,235	February 23, 1999	Chan, et al			
	AQ	5,891,622	April 6, 1999	Morrow, et al.			
	AR	5,945,675	August 31, 1999	Malins			
	AS	5,958,978	September 28, 1999	Yamazaki, et al.			
	AT	5,973,191	October 26, 1999	Marnett, et al.			
	AU	5,995,645	November 30, 1999	Soenksen, et al.			
	AV	5,999,843	December 7, 1999	Anbar			
	AW	6,045,773	April 4, 2000	Isakson, et al.			
	AX	6,107,049	August 22, 2000	Allard, et al.			
<b>MISCELLANEOUS DOCUMENTS</b>							
	AY	KALGUTAR, et al.; Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors; PNAS January 18, 2000; 97(2) 925-930.					
	AZ	KOZAK, et al.; Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glycerol Prostaglandins by Cyclooxygenase-2; The Journal of Biological Chemistry October 27, 2000; 43:33744-33749.					
	BA	KOZAK, et al.; Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol; JBP Papers in Press June 11, 2001					
	BB	LANDS, et al.; Phospholipid precursors of prostaglandins; Biochem. Biophys. Acta 1968; 164:426-429.					
	BC	PRESCOTT; A thematic series on oxidation of lipids as a source of messengers; J.Biol. Chem.; 274:22901.					
<b>Examiner:</b>				<b>Date Considered</b>			
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

cited on 1449 filed 1/8/02


✓



RECEIVED

222001

cited in 1449 find 1/8/02



Comparable to  
E-TRADE-1449

**U.S. Department of Commerce  
Patent & Trademark Office**

**Atty. Docket No.**

Serial No.

**N-6138 RSM**  
**Customer No. 23456**

09/923,63

**Applicant**

Lawrence J. Marnett, et al.

Filing Date  
August 7, 2001

**Group**

1651

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

TECH CENTER 1600/2900

Page 3 of 3

JAN 22 2017

RECEIVED

**MISCELLANEOUS DOCUMENTS**

**Examiner:**

**Date Considered**

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

cited in 1449 f69 1/8/02